Accord Healthcare Launches Dehydrated Alcohol Injection for Cardiovascular Indications
Dehydrated Alcohol is approved by the FDA and is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy1.
"The launch of Accord Healthcare's Dehydrated Alcohol Vials represents a meaningful advancement in offering a more convenient alternative to the traditional ampule market," said Chrys Kokino, President of Accord Healthcare US. "It reflects our ongoing commitment to improving access and efficiency for healthcare providers."
Important Safety Information
Transient heart block is common at the time of injection and is typically managed with the routine use of a temporary pacing wire. In approximately 10% of cases, complete heart block may become permanent, requiring a permanent pacemaker. The temporary pacing lead should be removed if no high-degree atrioventricular block occurs. Patients should be monitored for signs of heart failure, chest pain, and arrhythmias in the days following the procedure.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord Healthcare is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord Healthcare is headquartered in Raleigh, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord Healthcare website.
References:
Dehydrated Alcohol Injection. Prescribing Information. Accord Healthcare; June 2025.
Media Contact:Lauren WheelerEmail: 396890@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-healthcare-launches-dehydrated-alcohol-injection-for-cardiovascular-indications-302490056.html
SOURCE Accord Healthcare US
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
26 minutes ago
- Bloomberg
Apple Watch Blood Oxygen Tracker Returns to US After Legal Win
Apple Inc.'s blood oxygen tracking feature for its smartwatch is returning to the US after a yearslong legal fight. The feature — which was removed at the end of 2023 due to a patent infringement lawsuit by Masimo Corp. and a US Customs injunction — will return for Apple Watch owners who bought models with the feature disabled, Apple said in a statement on Thursday.
Bloomberg
26 minutes ago
- Bloomberg
Lilly Hikes UK Obesity Shot Price as Trump Pressures Drugmakers
Photographer: George Frey/Bloomberg Eli Lilly & Co. is raising the list price for its obesity shot in the UK, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. The current list price in the UK for Lilly's obesity drug Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose. The new list price will see this increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries.
The Verge
26 minutes ago
- The Verge
Apple returns blood oxygen monitoring to the latest Apple Watches
Blood oxygen monitoring is returning to the Apple Watch — sort of. Starting today, Apple is rolling out a software update that enables a redesigned version of the feature for the Apple Watch Series 9, 10, and Ultra 2 that circumvents the import ban imposed by the International Trade Commission. To get around the ban, blood oxygen data collected on the Watch will now be measured and calculated on the iPhone that it's paired to. While users won't be able to view the data on their wrist, they'll be able to view it in the iPhone's Health app under the Respiratory section. Apple's announcement states that US customs has ruled that the company will be able to import watches with this redesigned feature. This redesign only covers Apple Watches sold after January 17th, 2024, once the ITC import ban took full effect. It doesn't impact models sold before that date or watches sold outside the US, all of which still have the original blood oxygen feature. You can tell if you have a covered model by checking if the serial number ends with LW/A. To get the redesigned feature, people with Series 9, 10, and Ultra 2 watches will have to update their devices to watchOS 11.6.1 and their iPhones to iOS 18.6.1. Apple has been in a lengthy legal dispute with Masimo, a medical device maker known for its pulse oximeters. Masimo alleged that Apple had infringed on several of its patents, filing a suit in 2020 accusing the company of stealing trade secrets. Masimo separately filed a case with the ITC in 2021, which culminated in an import ban in December 2023. Apple has also lodged suits against Masimo over its smartwatches, which it claims are Apple Watch clones. It also filed a 916-page appeal of the ITC ban. That appeal is currently ongoing and Masimo's patents are set to expire in 2028. Posts from this author will be added to your daily email digest and your homepage feed. See All by Victoria Song Posts from this topic will be added to your daily email digest and your homepage feed. See All Apple Posts from this topic will be added to your daily email digest and your homepage feed. See All Gadgets Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Science Posts from this topic will be added to your daily email digest and your homepage feed. See All Smartwatch Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech Posts from this topic will be added to your daily email digest and your homepage feed. See All Wearable
